Luis E. Rohde, MD, ScD; Marciane M. Rover, MD; Conrado R. Hoffmann Filho, MD; et al.
JAMA Cardiol. 2024;9(2):105-113. doi:10.1001/jamacardio.2023.4501
This randomized clinical trial evaluates the feasibility and efficacy of an intensive telemonitoring strategy in the vulnerable period after a heart failure hospitalization.
Gad Cotter, MD; Benjamin Deniau, MD, PhD; Beth Davison, PhD; et al.
open access
JAMA Cardiol. 2024;9(2):114-124. doi:10.1001/jamacardio.2023.4553
This secondary analysis of the Safety, Tolerability, and Efficacy of Rapid Optimization, Helped by N-Terminal Pro鈥揃rain Natriuretic Peptide Testing of Heart Failure Therapies (STRONG-HF) randomized clinical trial investigates what variables are associated with success in uptitration of guideline-directed medical therapy after hospital discharge for an acute heart failure admission.
-
Editorial
STRONG-HF Evidence for Proactive, Patient-Centered Prescribing
Larry A. Allen, MD, MHS; Jocelyn S. Thompson, MA; Josef Stehlik, MD, MPH
JAMA Cardiol
Myunhee Lee, MD; Sungwook Byun, MD, PhD; Sungmin Lim, MD, PhD; et al.
JAMA Cardiol. 2024;9(2):125-133. doi:10.1001/jamacardio.2023.4587
This post hoc analysis of the Ticagrelor vs Clopidogrel in Stabilized Patients With Acute Myocardial Infarction (TALOS-AMI) randomized clinical trial investigates the efficacy and safety of the de-escalation strategy of switching from ticagrelor to clopidogrel vs dual antiplatelet therapy with ticagrelor in stabilized patients with acute myocardial infarction and high ischemic risk.
Nikolaus Marx, MD; Ahmed A. Kolkailah, MD, MSc; Julio Rosenstock, MD; et al.
open access
JAMA Cardiol. 2024;9(2):134-143. doi:10.1001/jamacardio.2023.4602
This secondary analysis evaluates antihyperglycemic treatments, hypoglycemic episodes, and risk for cardiovascular events and mortality in 2 randomized clinical trials involving adults with type 2 diabetes.
Finnian R. Mc Causland, MBBCh, MMSc; Brian L. Claggett, PhD; Muthiah Vaduganathan, MD, MPH; et al.
open access
JAMA Cardiol. 2024;9(2):144-152. doi:10.1001/jamacardio.2023.4664
This prespecified analysis of the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) randomized clinical trial investigates the association of initial changes in estimated glomerular filtration rate with cardiovascular and kidney outcomes in patients with heart failure and mildly reduced or preserved ejection fraction.
Social Determinants of Health
Michael Liu, MPhil; Vishal R. Patel, BS; Renee N. Salas, MD, MPH, MS; et al.
free access
JAMA Cardiol. 2024;9(2):153-163. doi:10.1001/jamacardio.2023.4680
This cross-sectional study evaluates associations between environmental burden and cardiovascular risk factors and diseases at the neighborhood level and by levels of social vulnerability.
-
Invited Commentary
Prioritizing the Exposome to Reduce Cardiovascular Disease Burden
Erica S. Spatz, MD, MHS; Kai Chen, PhD; Harlan M. Krumholz, MD, SM
JAMA Cardiol
Rosa B. Thorolfsdottir, MD, PhD; Andrea B. Jonsdottir, MD; Gardar Sveinbjornsson, MSc; et al.
JAMA Cardiol. 2024;9(2):165-172. doi:10.1001/jamacardio.2023.4820
This genome-wide association study reports associations between pericarditis and sequence variants at the interleukin 1 gene locus.
AI in Cardiology
Jonathan W. Cunningham, MD, MPH; Pulkit Singh, BA; Christopher Reeder, PhD; et al.
free access
JAMA Cardiol. 2024;9(2):174-181. doi:10.1001/jamacardio.2023.4859
This secondary analysis of a randomized clinical trial validates the findings of a single-center study regarding the use of natural language processing for the adjudication of heart failure hospitalization.
-
Editorial
The Future of Clinical Trials: Artificial to Augmented to Applied Intelligence
Adrian F. Hernandez, MD, MHS; Christopher J. Lindsell, PhD
JAMA
-
Innovation in Event Adjudication鈥擧uman vs Machine
Kenneth W. Mahaffey, MD; C. Michael Gibson, MS, MD; Renato D. Lopes, MD, MHS, PhD
JAMA Cardiol